Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | TAF1 | P21675 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10127720 | 0.91 | GRIN2B (0.48) | QDPRADRA2CHTR1DHTR1BTAF1 | |
| SCHEMBL273350 | 0.82 | CYP3A4 (0.50) | HDAC4HDAC2HDAC8 | |
| SCHEMBL29411064 | 0.82 | CYP3A4 (0.50) | HDAC4HDAC2HDAC8 | |
| SCHEMBL6687409 | 0.82 | DRD2 (0.69) | DRD2DRD1SIGMAR1 | |
| SCHEMBL13363066 | 0.82 | DDB1 (0.40) | ADRA2CDRD2SIGMAR1 | |
| SCHEMBL28322710 | 0.81 | DRD2 (0.52) | DRD2DRD1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL30689998 | 0.81 | DRD2 (0.68) | DRD2DRD1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL26666899 | 0.81 | DRD2 (0.68) | DRD2DRD1SIGMAR1 | |
| SCHEMBL4765378 | 0.81 | ADRA2C (0.41) | QDPRADRA2CHTR1DHTR1BDRD2 | |
| Hydrochloric Acid SCHEMBL25305777 | 0.81 | CYP3A4 (0.48) | HDAC4HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024262911-A1 | NOVEL PYRAZOLO PYRIMIDINE-BASED COMPOUND AND USE THEREOF | 주식회사 에이조스바이오 | 2024-12-26 | — | — | WO | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Hongyun Biotech Co., Ltd. (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2023011610-A1 | BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| WO-2021249324-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 南京红云生物科技有限公司 | 2021-12-16 | — | — | WO | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487491-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2016-11-08 | — | — | US | disclosed |
| EP-2428508-B9 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-2428508-B1 | DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-12-16 | — | — | EP | disclosed |
| US-8969336-B2 | Diamino heterocyclic carboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| CN-1167686-C | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | О | 2004-09-22 | — | — | CN | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-6649609-B2 | For inducing and maintaining anesthesia, sedation and muscle relaxation, as well as for combating febrile convulsions in children | NEUROSEARCH A/S (DK) | 2003-11-18 | — | — | US | disclosed |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | ANIONA APS (DK) | 2003-03-20 | — | — | US | disclosed |
| CN-1356987-A | Novel benzimidazole derivatives and pharmaceutical compsns. comprising these compounds | NEUROSEARCH AS (DK) | 2002-07-03 | — | — | CN | disclosed |
| EP-1194410-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
| US-6159979-A | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-12 | — | — | US | disclosed |
| EP-0975614-A1 | A BICYCLIC ARYL OR A BICYCLIC HETEROCYCLIC RING CONTAINING COMPOUNDS HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047885-A1 | A BICYCLIC ARYL OR A BICYCLIC HETEROCYCLIC RING CONTAINING COMPOUNDS HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ANTAGONISTIC ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212147-A1 | ALKENYL PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, EGFR, WEE2 | QDPR 602/4885ADRA2C 4280/4885HTR1D 2816/4885 |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | QDPR 732/4885ADRA2C 40/4885HTR1D 1776/4885 |
| US-20030055055-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | QDPR 634/4885ADRA2C 39/4885HTR1D 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.